Shares of Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) traded down 5.6% during trading on Thursday . The company traded as low as $15.05 and last traded at $15.56. 68,373 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 201,986 shares. The stock had previously closed at $16.48.
Analyst Upgrades and Downgrades
SION has been the subject of a number of research analyst reports. Guggenheim began coverage on shares of Sionna Therapeutics in a research report on Tuesday. They set a “buy” rating and a $45.00 price objective for the company. TD Cowen started coverage on Sionna Therapeutics in a research note on Tuesday. They issued a “buy” rating for the company. Finally, Stifel Nicolaus initiated coverage on Sionna Therapeutics in a research report on Tuesday. They set a “buy” rating and a $32.00 price objective on the stock.
View Our Latest Stock Analysis on Sionna Therapeutics
Sionna Therapeutics Stock Down 4.1 %
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
- Five stocks we like better than Sionna Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- Insider Trading – What You Need to Know
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Taiwan Semi’s $100 Billion Investment: Fate of the Chipmakers
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
